BlackRock Institutional Trust’s KalVista Pharmaceuticals KALV Stock Holding History

BlackRock Institutional Trust’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3K	Sell	362 -1	-0.3%	-$7	﹤0.01%	3817
2016 Q3	$2K	Hold	363	–	–	﹤0.01%	3861
2016 Q2	$3K	Sell	363 -5,476	-94%	-$63.4K	﹤0.01%	3870
2016 Q1	$53K	Sell	5,839 -85	-1%	-$1.52K	﹤0.01%	3785
2015 Q4	$300K	Buy	5,924 +91	+2%	+$4.76K	﹤0.01%	3584
2015 Q3	$292K	Buy	5,833 +353	+6%	+$30.1K	﹤0.01%	3587
2015 Q2	$549K	Buy	+5,480	New	+$544K	﹤0.01%	3494

Other funds holding KALV

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Institutional Trust's KALV Position: Q4 2016 in Review

BlackRock Institutional Trust reduced its KalVista Pharmaceuticals (KALV) stake by 0.28% in Q4 2016, selling an estimated $7 and leaving 362 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

BlackRock Institutional Trust first reported a position in KALV in Q2 2015 and has held it in 7 quarters since. The position peaked at $549K in Q2 2015. 20 funds tracked by Wall St. Rank hold KALV as of Q4 2016.

BlackRock Institutional Trust held 362 shares of KalVista Pharmaceuticals worth $3K as of Q4 2016.
BlackRock Institutional Trust sold 1 KalVista Pharmaceuticals share in Q4 2016, an estimated $7.
KalVista Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3817 holding.
BlackRock Institutional Trust first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 7 quarters since.
BlackRock Institutional Trust's KalVista Pharmaceuticals position peaked at $549K in Q2 2015.
20 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.